Antimicrobial resistance (AMR) is the ability of microorganisms that cause disease to withstand attack by antimicrobial medicines…

1. Antimicrobial Resistance

2. Can We kill Antibiotic-Resistant Super Bugs?
?

3. What Is AMR?
 Antimicrobial resistance (AMR) is the ability of
microorganisms that cause disease to withstand
attack by antimicrobial medicines
 AMR is rapidly becoming a major
public health risk and is threatening
to undo decades of advances in
treating disease

4.  Increased use of antibiotics
 Prescriptions taken incorrectly
 Sold without medical supervision
 Prophylactic use before surgery
 Antibiotics used for viral infection
 Spread of resistant microbes in hospitals due to lack of hygiene
 Patients who do not complete course
 Antibiotics in animal feeds
What Has Led To Resistance?

5. Methods of Resistance
 Impermeability of the drug
 Alteration in the drug’s target
 Enzymatic drug modification
 Efflux of the drug
Methods of Resistance Acquisition
 Chromosomal mutation
 Genetic transfer (ex: plasmids)
Mechanisms Of Resistance: Overview

6. Superbug Statistics
Death From Drug-Resistance Infection Set To Skyrocket
Deaths from antimicrobial resistant infections and other causes in 2050
Antimicrobial resistant
infections
10.0 m
Cancer 8.2m
Diabetes 1.5m
Diarrhoeal Disease 1.4
Road traffic accident 1.2m
Measles 130,000
Cholera 120,000

7. The latest investment stats from CARB-X
Pharmaceutical Companies and the Superbugs War
0
5
10
15
20
25
30
27 22 09 16 14 08 22 12
Large Research Based Pharmaceutical Companies.
0
5
10
15
20
7 17 7 10 4 10 11 6
7 11 11 10
Pharmaceutical and biopharmaceutical companies leading the charge against superbugs
Bio Pharmaceutical Companies.
3
8
21
9
16
12
8
13
13 13
3
13
5
16
10
9 9 9
10
14
R & D
Remaining potential score
Money For The War On Superbugs

8. Rethink The Way Fighting Bugs:
WHO WE ARE?
 A strong inter-disciplinary team of 150 scientists.
WHAT WE DO?
 We aim to provide effective, safe and robust treatment that target Gram-
negative bacteria ,especially the bacteria involved in nosocomial and urinary
tract infection.

9.  Gram-Negative Bacterial Infections
 Massive Urgent GLOBAL Unmet Need
 Causes many life-threatening illnesses
 Pneumonia, Sepsis, complicated urinary tract infections, post-surgical
intra-abdominal infections, burn injury infections etc.
 Key Culprits
 Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella
pneumoniae, Escherichia coli, Enterobacter spp. etc.
 No new Gram-negative antibiotic since 1962
 WHY: Extremely Well Protected
 Permeability barriers for entry
Multiple Efflux Pumps
Focus Area

10. Our Technologies:
1. Developing new molecules or derivatives of existing antibiotics with same or
different MoA:
Super Bugs Need Drugs
Entry into Phase 1 clinical trials
Preclinical development
Candidate Declartion
Drug delivery,
extensive in vivo
efficacy profiling

11. 2. Efflux Avoidance Technology:
Super Bugs Need Drugs
Super Bugs Need Drugs

12. Stabicon’s Initiative On Anti Microbial Resistance
11 formulations developed and analyzed
 Two(2) positive potential
̶ Greater solubility
̶ Effective in by passing fast pass metabolism
̶ Improved targeted delivery
̶ Boost up immunity

13. Let’s meet and discuss
Business Model

14. Business Model
Business Development Team
+91 80 41250324
bd@stabicon.com
www.stabicon.com